Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-04-08 4:10 pm Purchase | 2024-04-01 | 13G | Outlook Therapeutics, Inc. OTLK | Great Point Partners, LLC | 2,231,324 9.990% | 2,231,324 (New Position) | Filing History |
| 2024-02-14 4:39 pm Unchanged | 2023-12-31 | 13G | Zura Bio Limited ZURA | Great Point Partners, LLC | 3,295,000 7.560% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:39 pm Unchanged | 2023-12-31 | 13G | VistaGen Therapeutics, Inc. VTGN | Great Point Partners, LLC | 2,792,927 9.990% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:38 pm Unchanged | 2023-12-31 | 13G | UroGen Pharma Ltd. URGN | Great Point Partners, LLC | 2,620,545 8.490% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:38 pm Purchase | 2023-12-31 | 13G | OptiNose, Inc. OPTN | Great Point Partners, LLC | 765,608 9.990% | 11,293 (+1.50%) | Filing History |
| 2024-02-14 4:37 pm Purchase | 2023-12-31 | 13G | Neurogene Inc. NGNE | Great Point Partners, LLC | 994,229 7.750% | 25,000 (+2.58%) | Filing History |
| 2024-02-14 4:37 pm Sale | 2023-12-31 | 13G | Heron Therapeutics, Inc. HRTX | Great Point Partners, LLC | 0 0.000% | -6,360,161 (Position Closed) | Filing History |
| 2024-02-14 4:37 pm Sale | 2023-12-31 | 13G | Precision BioSciences, Inc. DTIL | Great Point Partners, LLC | 0 0.000% | -269,993 (Position Closed) | Filing History |
| 2024-02-14 4:36 pm Purchase | 2023-12-31 | 13G | Avalo Therapeutics, Inc. AVTX | Great Point Partners, LLC | 2,085 0.260% | 2,085 (New Position) | Filing History |
| 2024-02-14 4:36 pm Purchase | 2023-12-31 | 13G | Alpine Immune Sciences, Inc. ALPN | Great Point Partners, LLC | 3,703,433 6.370% | 65,715 (+1.81%) | Filing History |
| 2023-12-27 4:03 pm Purchase | 2023-12-18 | 13G | Neurogene Inc. NGNE | Great Point Partners, LLC | 969,229 7.560% | 969,229 (New Position) | Filing History |
| 2023-10-12 4:04 pm Purchase | 2023-10-02 | 13G | VistaGen Therapeutics, Inc. VTGN | Great Point Partners, LLC | 2,792,927 9.990% | 2,792,927 (New Position) | Filing History |
| 2023-09-15 1:39 pm Purchase | 2023-09-08 | 13G | UroGen Pharma Ltd. URGN | Great Point Partners, LLC | 2,620,545 8.510% | 2,620,545 (New Position) | Filing History |
| 2023-06-16 1:31 pm Purchase | 2023-06-05 | 13G | Zura Bio Limited ZURA | Great Point Partners, LLC | 3,295,000 7.650% | 3,295,000 (New Position) | Filing History |
| 2023-04-13 1:58 pm Purchase | 2022-11-02 | 13G | Heron Therapeutics, Inc. HRTX | Great Point Partners, LLC | 6,360,161 5.350% | 6,360,161 (New Position) | Filing History |
| 2023-02-27 3:40 pm Purchase | 2023-02-17 | 13G | Precision BioSciences, Inc. DTIL | Great Point Partners, LLC | 269,993 7.300% | 143,283 (+113.08%) | Filing History |
| 2023-02-14 5:00 pm Unchanged | 2022-12-31 | 13G | OptiNose, Inc. OPTN | Great Point Partners, LLC | 754,315 9.990% | 0 (Unchanged) | Filing History |
| 2023-02-14 4:59 pm Sale | 2022-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV | Great Point Partners, LLC | 1,055,801 3.100% | -224,199 (-17.52%) | Filing History |
| 2023-02-14 4:58 pm Sale | 2022-12-31 | 13G | 89bio, Inc. ETNB | Great Point Partners, LLC | 700,000 1.370% | -1,400,000 (-66.67%) | Filing History |
| 2023-02-14 4:58 pm Sale | 2022-12-31 | 13G | Precision BioSciences, Inc. DTIL | Great Point Partners, LLC | 126,710 3.430% | -65,136 (-33.95%) | Filing History |